Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs
article
OA: closed
CC0
⤵ 1 in-corpus citation
Abstract
The usefulness of selected conventional surfactant media to enhance dissolution of BCS class II drugs similarly to fasted state simulated intestinal fluid (FaSSIF) and to predict the absorption of drugs in vivo was evaluated. Dissolution behavior of danazol (Danol), spironolactone (Spiridon) and N74 (phase I compound) was compared between FaSSIF, containing physiological levels of sodium taurocholate (STC) and lecithin, and dissolution media containing various concentrations of anionic surfactant, sodium lauryl sulfate (SLS) or non-ionic surfactant, polysorbate (Tween) 80. Although these media differed largely in their solubilization ability, micelle size, diffusivity and surface tension, similar dissolution enhancing levels were achieved between FaSSIF and drug-specific concentrations of conventional surfactants. The dissolution enhancement was shown, however, to be important only for danazol and N74, molecules that are characterized by high hydrophobicity. An in vivo pharmacokinetic dog study was carried out with N74. Comparison of observed plasma profiles with simulated profiles obtained using compartmental absorption and transit model (CAT) indicated that 0.1% SLS medium was the best to predict in vivo plasma profiles and pharmacokinetic parameters (C(max) and AUC). This study demonstrates the potential of substituting FaSSIF with more simple and cost-effective conventional surfactant media. Use of in vivo prognostic amounts of synthetic surfactants in dissolution testing could largely assist in industrial drug development as well as in quality control purposes.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (1)
References (32)
- In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media via openalex
- W164496576 via openalex
- doi:10.1023/a:1019858428449 via openalex
- doi:10.1016/s0169-409x(01)00182-x via openalex
- doi:10.1002/jps.20494 via openalex
- doi:10.1016/j.ejpb.2007.12.013 via openalex
- doi:10.1023/a:1011984216775 via openalex
- doi:10.1002/jps.10329 via openalex
- doi:10.1023/a:1016212804288 via openalex
- doi:10.1111/j.2042-7158.1975.tb09378.x via openalex
- doi:10.1016/j.ejps.2006.10.011 via openalex
- doi:10.1016/0378-5173(96)04592-9 via openalex
- doi:10.1016/s0927-7765(03)00148-6 via openalex
- W2476683829 via openalex
- W3217585462 via openalex
- W6654888720 via openalex
- W6703591683 via openalex
- doi:10.1016/s0016-5085(19)34581-0 via openalex
- doi:10.1023/a:1018961227717 via openalex
- doi:10.1016/j.ejpb.2007.12.010 via openalex
- doi:10.1016/j.ijpharm.2005.05.004 via openalex
- doi:10.1016/j.ejps.2006.05.004 via openalex
- doi:10.1023/a:1007517414200 via openalex
- doi:10.1023/a:1011910801212 via openalex
- doi:10.1016/j.ejps.2007.05.110 via openalex
- doi:10.14227/dt110204p16 via openalex
- doi:10.1023/a:1016353705970 via openalex
- doi:10.14227/dt070100p8 via openalex
- doi:10.1023/a:1016316730560 via openalex
- doi:10.1023/a:1018907527253 via openalex
- doi:10.1023/a:1011071401306 via openalex
- doi:10.1002/jps.10419 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-11T05:50:48.314143+00:00
License: CC0
· commercial use OK